pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
← back to Sanofi

News mentioning $SNY

309 stories

12dSanofi-backed Windward breezes toward $204M IPO to fund respiratory pipeline from Chinafiercebiotech
14dCould we see 10 Chinese Big Pharmas within a decade? Some CEOs think sofiercebiotech
14dVerdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked Novemberbiospace
15dT-time: British biotech pours $133M into the pot for bispecificsbiospace
16dThe top 12 companies hiring in biopharma nowbiospace
16dT-Therapeutics secures $133M for cancer, autoimmune TCRsendpoints
16dSanofi stops development of Nurix-partnered immune drugbiopharma dive
16dSanofi ends development of Nurix's STAT6 degraderendpoints
16dSanofi’s axing of Nurix STAT6 program ‘not a target-related issue’biospace
16dQ3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches reviewbiospace
17dSanofi scraps STAT6 degrader from Nurix just 2 months after entering clinicfiercebiotech
17dT-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in towfiercebiotech
18dAbbVie invests £120M in UK, including expanded R&D sitefiercebiotech
18dEarnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resiliencebiopharma dive
19dSTAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixentstat
19dCan Saudi Arabia's burgeoning biotech hub withstand geopolitical pressures?biospace
21dSanofi may seek higher European drug prices, not withhold launches, under Trump dealendpoints
21dRegeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckbiospace
21dSanofi targets late-phase and commercial M&A to offset looming Dupixent declinebiospace
21d‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchisebiospace
21dSanofi has no plans for 'major restructuring' as Dupixent's patent cliff loomsendpoints
22dNew biotech Setara forms with $90M to take on Jazz’s bonus rare disease programsbiospace
22dSanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent clifffiercebiotech
22dDren Bio lands $350M to push rare blood cancer therapy toward marketbiospace
23dBioMarin inks up to $475M deal to challenge Fabry ERT incumbentsfiercebiotech
23d8 companies hiring in New Yorkbiospace
24dBehind the scenes of 3 Big Pharma layoffsbiospace
24dAlphabet’s GV is one of biotech’s most influential corporate investorsbiospace
28dSTAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trialsstat
28dAl Sandrock to step down as Voyager CEO; Insmed adds Paul Hudson to boardendpoints
← prevpage 2 of 11next →